Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 6 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.

Adjunctive brivaracetam safe, effective for long-term treatment of patients with epilepsy

27 Apr 2020

Long-term use of brivaracetam as an adjunctive treatment is well tolerated and effective in patients with focal seizures or primary generalized seizures (PGS), as shown in a study.

The study included patients aged ≥16 years who had completed double‐blind, placebo‐controlled adjunctive brivaracetam trials. Safety analysis involved 652 patients with focal seizures and 15 with PGS, while efficacy analysis comprised 648 and 15 patients, respectively.

Overall, 49.2 percent of patients had ≥48 months of exposure to the drug. Treatment‐emergent adverse events (TEAEs) occurred in 608 patients (91.2 percent), including 595 (91.3 percent) with focal seizures. Brivaracetam discontinuation was reported in 14.8 percent of patients due to TEAEs, in 56.7 percent due to drug‐related TEAEs, and in 22.8 percent due to serious TEAEs. Common reported TEAEs in the focal seizures group were headache (25.3 percent) and dizziness (21.9 percent).

Mean changes from baseline in anxiety and depression (measured using the Hospital Anxiety and Depression Scale) over the 2‐year evaluation period were −0.7 and −0.2, respectively.

In terms of efficacy, median reduction from baseline in focal seizure frequency per 28 days was 57.3 percent. The 50-percent responder rate was 55.6 percent, with 6‐ and 12‐month seizure freedom rates of 30.3 percent and 20.3 percent, respectively.

Efficacy outcomes improved with increasing duration of exposure to brivaracetam, with changes remaining stable through 9 years. Quality of life also improved. Mean improvement in Patient‐Weighted Quality of Life in Epilepsy Inventory total score (efficacy set) from baseline were 5.7 at month 12 and 6.5 at month 24.

The present data support the long‐term use of adjunctive brivaracetam to treat patients with focal seizures, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 6 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.